Literature DB >> 12708727

Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women.

Naomi E Allen1, Paul N Appleby, Rudolf Kaaks, Sabina Rinaldi, Gwyneth K Davey, Timothy J Key.   

Abstract

OBJECTIVE: This study aims to identify the lifestyle determinants of insulin-like growth factor-I (IGF-I) and its main binding proteins (IGFBPs), C-peptide, and sex hormone-binding globulin (SHBG) to help elucidate the mechanism through which lifestyle factors may affect cancer risk.
METHODS: This study is based on a sample of 292 British women, aged 20-70 years, whose lifestyle characteristics were assessed using a self-administered questionnaire and whose serum hormone concentrations were measured using immunoassays.
RESULTS: Age was a strong determinant of both IGF-I and IGFBP levels; women aged 65-70 years had significantly lower IGF-I and IGFBP-3 concentrations and significantly higher IGFBP-1 and IGFBP-2 concentrations than women aged 20-24 years. Body mass index (BMI) was not strongly associated with IGF-I, although women with a BMI of 26-27.9 kg/m2 had a higher IGF-I concentration compared with both lean (BMI <20 kg/m2) and obese (BMI 30+ kg/m2) women. However, obese women had a significantly higher C-peptide and IGFBP-3 concentration and a significantly lower IGFBP-1, IGFBP-2, and SHBG concentration compared with lean women. Increasing vigorous exercise was associated with a significantly lower C-peptide concentration and increasing leisure-time activity was associated with a significantly higher IGFBP-1 concentration. Other lifestyle factors such as job activity, smoking, and reproductive factors were not associated with any hormone.
CONCLUSIONS: Our data show that age is a major determinant of both IGF-I and its main binding proteins in women. BMI has strong effects on IGFBPs, C-peptide, and SHBG, but its effects on IGF-I remain unclear. The possible effect of physical activity on IGFBP-1 requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708727     DOI: 10.1023/a:1022518321634

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  24 in total

1.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

2.  The effect of oral contraceptive different patterns of use on circulating IGF-1 and bone mineral density in healthy premenopausal women.

Authors:  Amany Y Elkazaz; Khaled Salama
Journal:  Endocrine       Date:  2014-05-27       Impact factor: 3.633

3.  Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.

Authors:  Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2013-03-02       Impact factor: 4.872

4.  Maternal hormones during early pregnancy: a cross-sectional study.

Authors:  Tianhui Chen; Eva Lundin; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Marianne Wulff; Yelena Afanasyeva; Helena Schock; Robert Johansson; Per Lenner; Goran Hallmans; Goran Wadell; Paolo Toniolo; Annekatrin Lukanova
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

5.  Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender.

Authors:  Jessica M Faupel-Badger; David Berrigan; Rachel Ballard-Barbash; Nancy Potischman
Journal:  Ann Epidemiol       Date:  2009-12       Impact factor: 3.797

6.  Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men.

Authors:  Cathrine Hoyo; Janet Grubber; Wendy Demark-Wahnefried; Bruce Lobaugh; Amy S Jeffreys; Steven C Grambow; Jeffrey R Marks; Temitope O Keku; Phillip J Walther; Joellen M Schildkraut
Journal:  J Natl Med Assoc       Date:  2009-07       Impact factor: 1.798

7.  Energy balance, insulin resistance biomarkers, and breast cancer risk.

Authors:  Alecia Malin Fair; Qi Dai; Xiao-Ou Shu; Charles E Matthews; Herbert Yu; Fan Jin; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Detect Prev       Date:  2007-07-23

8.  Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial.

Authors:  Hsin-Chieh Yeh; Nisa M Maruthur; Nae-Yuh Wang; Gerald J Jerome; Arlene T Dalcin; Eva Tseng; Karen White; Edgar R Miller; Stephen P Juraschek; Noel T Mueller; Jeanne Charleston; Nowella Durkin; Ahmed Hassoon; Dina G Lansey; Norma F Kanarek; Michael A Carducci; Lawrence J Appel
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

9.  Association of serum C-peptide concentrations with cancer mortality risk in pre-diabetes or undiagnosed diabetes.

Authors:  Chih-Neng Hsu; Chia-Hsuin Chang; Yu-Sheng Lin; Jou-Wei Lin; James L Caffrey
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Long-term and baseline recreational physical activity and risk of endometrial cancer: the California Teachers Study.

Authors:  C M Dieli-Conwright; H Ma; J V Lacey; K D Henderson; S Neuhausen; P L Horn-Ross; D Deapen; J Sullivan-Halley; L Bernstein
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.